Literature DB >> 23608447

The role of radiotherapy in the overall treatment of melanoma.

Andrea Forschner1, Vanessa Heinrich, Annette Pflugfelder, Friedegund Meier, Claus Garbe.   

Abstract

Radiotherapy has become an effective treatment in the management of melanoma patients. It has its place beneath surgical treatment options in a tumor entity that has only limited response to systemic medical therapies. New therapies, such as ipilimumab and vemurafenib, may prolong survival for several months but will cure only a few patients. Radiotherapy will still be required in adjuvant settings to reduce the local recurrence rate and in palliative situations, particularly in brain and bone metastasis. We review several indications for radiotherapy in the management of malignant melanoma with an effect on the guidelines in our clinical practice.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23608447     DOI: 10.1016/j.clindermatol.2012.08.009

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  4 in total

1.  Palliative radiotherapy for Japanese patients with malignant melanoma: a single-institution experience.

Authors:  Keiichiro Koiwai; Shigeru Sasaki; Eriko Yoshizawa; Hironobu Ina; Ayumu Fukazawa; Katsuya Sakai; Takesumi Ozawa; Hirohide Matsushita; Masumi Kadoya
Journal:  Jpn J Radiol       Date:  2015-12-14       Impact factor: 2.374

2.  Combined radiotherapy with nivolumab for extracranial metastatic malignant melanoma.

Authors:  Tetsuya Komatsu; Kenta Konishi; Masahiro Aoshima; Yoshiki Tokura; Katsumasa Nakamura
Journal:  Jpn J Radiol       Date:  2018-09-11       Impact factor: 2.374

Review 3.  Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma.

Authors:  Linli Zhou; Kun Yang; Thomas Andl; R Randall Wickett; Yuhang Zhang
Journal:  J Cancer       Date:  2015-06-23       Impact factor: 4.207

4.  A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes.

Authors:  Sreeja Sarojini; Andrew Pecora; Natasha Milinovikj; Joseph Barbiere; Saakshi Gupta; Zeenathual M Hussain; Mehmet Tuna; Jennifer Jiang; Laura Adrianzen; Jaewook Jun; Laurice Catello; Diana Sanchez; Neha Agarwal; Stephanie Jeong; Youngjin Jin; Yvonne Remache; Andre Goy; Alois Ndlovu; Anthony Ingenito; K Stephen Suh
Journal:  Melanoma Res       Date:  2015-10       Impact factor: 3.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.